Clinical Studies and Therapies in Parkinson's Disease

More than 50 years have passed since the use of L-dopa in the palliative treatment of Parkinson''s disease, but it remains the most common treatment despite inducing severe side effects such as dyskinesia after 4–6 years of use. Numerous preclinical investigations based on endogenous neurotoxin models have promised various therapies for Parkinson''s disease, but these efforts have failed　when atte...